These tetramer products are for detection of CEF virus-specific T cells
The CEF peptide pool was initially described by Currier and include a well-defined set of 23 virus-derived peptides from Cytomegalovirus (C), Epstein Bar virus (E) and Influenza (Flu, F) viruses. The CEF peptide pool is extensively used as a positive control for CD8 T cell activation.
Peptides from the CEF pool causes CD8+ T cells to produce various cytokines including IFN-γ and is recommended as a positive control in IFN-γ ELISpot assays using human peripheral blood mononuclear cells (PBMC). The CEF pool has been shown to induce IFN-γ responses in up to 90% of all Caucasians.
CEF virus-specific CD8+T cells can be detected in preparations of lymphoid cells from infected individuals by staining with virus-specific Tetramers followed by flow cytometry analysis. Amongst the original 23 described virus peptides in the CEF pool are 4 peptide antigens frequently detected in humans using tetramer assays.
>> Order CEF virus-specific Tetramers to monitor CEF response
| Cat. No. | HLA type | Pep. Seq. | Antigen |
| HA02-010 | HLA-A*02:01 | NLVPMVATV | HCMV pp65 495-504 |
| HA02-012 | HLA-A*0201 | GILGFVFTL | Influenza A MP 58-66 |
| HA02-011 | HLA-A*0201 | GLCTLVAML | EBV BMLF-1 259-267 |
| HB07-009 | HLA-B*0702 | RPPIFIRRL | EBV EBNA-3A 247-255 |
>> Order negative control Tetramers
| Cat. No. | HLA type | Pep. Seq. | Antigen |
| HA02-179 | HLA-A*0201 | ALAAAAAAV | Control |
| HA02-024 | HLA-A*0201 | AVIAPVHAV | Control |
>>Other virus-specific Tetramers not included in the CEF pool
| Cat. No. | HLA type | Pep. Seq. | Antigen |
| HA02-028 | HLA-A*02:01 | VLEETSVML | HCMV IE1 316-324 (UL123) |
| HB07-015 | HLA-B*07:02 | TPRVTGGGAM | HCMV pp65 417-426 |
| HB07-008 | HLA-B*07:02 | RPHERNGFTVL | HCMV pp65 265-275 |
| HA24-013 | HLA-A*24:02 | QYDPVAALF | HCMV pp65 341-349 |
| HA24-021 | HLA-A*24:02 | VYALPLKML | HCMV pp65 113-121 |
| HA02-016 | HLA-A*02:01 | CINGVCWTV | HCV NS3 1073-1081 |
| HA02-017 | HLA-A*02:01 | CLGGLLTMV | EBV LMP-2 426-434 |
| HA02-015 | HLA-A*02:01 | FLPSDFFPSV | HBV Core antigen 18-27 |
| HA02-026 | HLA-A*02:01 | FLYALALLL | EBV LMP-2 356-364 |
| HA02-018 | HLA-A*02:01 | ILKEPVHGV | HIV-1 RT 476-484 |
| HA02-013 | HLA-A*02:01 | LLMWEAVTV | VP1 BK virus |
| HA02-014 | HLA-A*02:01 | SLYNTVATL | HIV-1 gag p17 76-84 |
| HA02-022 | HLA-A*02:01 | YMLDLQPET | HPV 16 E7 11-19 |
| HA02-027 | HLA-A*02:01 | YVLDHLIVV | EBV BRLF1 109–117 |
Clinical relevance of CEF virus-specific Tetramers
More than 90% of the world population is or have been infected with CMV, EBV or influenza virus.
Virus infections and in particular latent virus represent a health risk for immunocompromised patients in lack of a sufficiently effective population of virus-specific T cells.
Patients in risk of virus outbreak include allogenic stem cell or organ transplant patients, AIDS/HIV patients, elderly or neonatal patients. Monitoring virus-specific CD8+ T cells can predict the immune status in immunocompromised individuals. Virus-specific Tetramers can also be used for evaluating efficacy of virus-specific vaccines.
Advantages of virus-specific Tetramer assays.
Viral detection based on PCR and antigen-detection can examine viral burden and identify a reactivation of latent virus. However, these assays cannot assess the patients’ capability to respond to virus since these assays give no information regarding the existence of virus-specific T cells. CD8+ T cells are the main control against viral infection and adequate levels of virus-specific CD8 T cells are known to defend against viral disease.
Application of Tetramers
Tetramers are useful for detection, enumeration and isolation of virus-specific CD8+ T cells in a variety of Research Use Only (RUO) applications. Please check our standard protocols.
Tetramer specification
Tetramer Store supply MHC Tetramers in various test sizes and the colors PE, BV421, BUV395, APC, BV510, BV480, BV605, BV650, BV786, BB515 and BUV737. For other colors, please enquire.